Dual specificity tyrosine-phosphorylation-regulated kinase 1B (DYRK1B) (DYRK1B)

Dual specificity tyrosine-phosphorylation-regulated kinase 1B (DYRK1B), also known as Mirk (Minibrain-related kinase), is a member of the DYRK family of protein kinases that plays a critical role in cell cycle regulation and survival. It functions as a dual-specificity kinase, autophosphorylating on tyrosine for activation and then phosphorylating substrates on serine/threonine residues. DYRK1B is a key mediator of cellular quiescence, promoting the G0 state by stabilizing the CDK inhibitor p27 and inducing the degradation of Cyclin D1. In oncology, DYRK1B is frequently overexpressed or amplified in cancers such as pancreatic, ovarian, and colorectal cancer, where it supports the survival of quiescent cancer cells and contributes to chemoresistance. Beyond its role in cancer, DYRK1B is essential for metabolic homeostasis; specific mutations in the gene are associated with Abdominal Obesity-Metabolic Syndrome 3 (AOMS3), which includes type 2 diabetes and coronary artery disease. The kinase also regulates differentiation in skeletal muscle, adipose tissue, and the testes. Therapeutic targeting of DYRK1B involves small molecule inhibitors like AZ191 and Harmine, as well as RNA interference strategies to reduce its expression. These interventions aim to sensitize resistant tumors to chemotherapy or to address metabolic dysregulation in patients with DYRK1B-related syndromes. However, challenges remain regarding the selectivity of inhibitors over the closely related DYRK1A and the potential for systemic metabolic side effects.

Other names

MirkMIRKAOMS3Dual specificity tyrosine-phosphorylation-regulated kinase 1B

Inhibition of kinase activity and reduction of mRNA levels via RNA interference.